---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219367"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2026-05-12T20:05:17+00:00"
generated_at: "2026-05-12T21:36:02.746546+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Immunome Q1 2026 net loss $53.8M; NDA filed for varegacestat; cash $582.7M

## Summary
- Net loss of $53.8M; R&D expenses $46.4M (incl. $3.7M stock comp); G&A $13.0M (incl. $4.2M stock comp).
- Cash and equivalents $582.7M at March 31, 2026; expected to fund operations into 2028.
- NDA submitted to FDA in April 2026 for varegacestat for desmoid tumors; Phase 3 RINGSIDE data selected for oral presentation at ASCO 2026.
- Phase 1 trial of IM-1021 ongoing with objective responses in B-cell lymphoma; initial lymphoma data expected in 2026.
- IND clearance for IM-1617 (first-in-class ADC) in April 2026; INDs for IM-1340 and IM-1335 planned mid/late 2026.

## SEC filing metadata
- accession: 0001193125-26-219367
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2026-05-12T20:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/0001193125-26-219367-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/imnm-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219367
- JSON: https://secwatch.observer/filing/0001193125-26-219367.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219367.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported the quarter ended March 31, 2026 results: net income net loss of $53.8 million.
  - Period: the quarter ended March 31, 2026
  - Net income: net loss of $53.8 million
  - Result: reported results
  source text: Immunome reported a net loss of $53.8 million for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000119312526219367/0001193125-26-219367-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.